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S_ary We report here the use of multiplex fluorescent polymerase chain reaction (PCR) for quantitative
allele loss detection using microsatellites with 2-5 base pair repeat motifs. Allele loss of APC, DCC, p53 and
RBI in colorectal tumours has been reported previously using a variety of methods. However, not all workers
used intragenic markers. We have used microsatellite polymorphisms which map within, or are closely linked
to, these tumour-suppressor gene loci in order to determine whether these loci are indeed the targets for
alteration in colorectal cancer. In addition, we have assayed two other tumour-suppressor genes, WT) and
NF1, to see whether they play a role in colorectal carcinogenesis. The putative metastasis-suppressor gene,
NM23, was also investigated since there have been conflicting reports about its involvement in colorectal
carcinogenesis. Allele loss was detected at the DCC (29%), p53 (66%), RBI (50%) and NFI (14%) loci and in
theAPC/MCC region (50%), but not at the WTI or NM23 loci. These rapid, and mostly gene-specific,
fluorescent multiplex PCR assays for allele loss detection could be modified to devise a single molecular
diagnostic test for the important lesions in colorectal cancer.
The progression of a colorectal tumour is a multistage pro-
cess involving activation of oncogenes and inactivation of
tumour-suppressor genes (Fearon & Vogelstein, 1990). If we
are to establish which are the most important genes in this
pathway we must be able to assay specific genes rapidly and
easily.
The p53, adenomatous polyposis coli (APC), deleted in
colorectal cancer (DCC) and retinoblastoma (RB)) genes are
tumour-suppressor genes which are implicated in this path-
way. To lose their suppressing effect, tumour-suppressor
genes have to undergo allele loss to uncover recessive muta-
tions in the remaining allele. Although loss of heterozygosity
is accepted to be a later event than mutation of a tumour-
suppressor gene, it is more widely studied because it is easier
to assay. Most tumour-suppressor genes display a wide array
of mutations and therefore require more time-consuming
assays. Allele loss assays are used to determine which
chromosome sites have undergone reduction to homozygo-
sity. There have been several reports on APC (5q21), DCC
(18q21) and p53 (17pl3) allele loss in colorectal tumours, but
not all used specific intragenic sequence polymorphisms to
determine whether the tumour-suppressor gene itself had
been lost. In almost all cases where intragenic restriction
fragment length polymorphisms (RFLPs) have been used
detection involved the use of a radiosotopic Southern blot
analysis. This type of assay requires large amounts of good-
quality DNA (and is therefore not suitable for the study of
paraffin-embedded specimens), is time consuming and is
usually subjective rather than quantitative. Therefore rapid
and reliable gene-specific quantitative PCR assays for allele
loss need to be developed in order that the true significance
of suppressor genes involved in colorectal cancer can be
confirmed on large series.
Most previous workers assessed the p53 gene region for
allele loss using Southern blot analysis. The frequencies of
allele loss of the p53 region found using this method ranged
from 48% (Lothe et al., 1992) to 68% (Meling et al., 1993).
RFLP probes and Southern blot analysis of the APC/MCC
region yielded allele loss frequencies of 31% (Neuman et al.,
1991) to 48% (Ashton-Rickardt et al., 1989). Again, most
previous work on allele loss of DCC was done using RFLP
probes and Southern analysis, with frequencies ranging from
66% (Barletta et al., 1993) to 75% (Ookawa et al., 1993).
However, a study using the same primers [DCC (1)] as our
study, which amplify an intragenic region, revealed an allele
loss frequency of only 33% (Huang et al., 1993).
Involvement of the RBI gene (13ql4) in colorectal cancer
has been shown by previous studies. Meling et al. (1991)
showed that RBI was altered in 35% of cases, using an
intragenic probe, but noted that both amplification and dele-
tion occurred. Ookawa et al. (1993) used markers at the RB)
locus and found allele loss in 46% of cases.
The importance of the NM23 gene (17q22) in colorectal
carcinogenesis is controversial since both allele loss and pro-
tein overexpression have been found, and other workers have
found no evidence of allele loss. Using RFLP probes allele
loss of NM23 was shown in 52% of cases by Cohn et al.
(1991), but in only 13% of cases by Wang et al. (1993).
However, Whitelaw and Northover (1994) found no evidence
of allele loss of NM23 in 34 informative cases. Further
studies of NM23 expression have confounded the picture
since increased expression of NM23 has been found in
80-88% of colorectal tumours (Haut et al., 1991; Myeroff &
Markowitz, 1993). Evidence for mutational activation, as
with p53, has not been found (Myeroff & Markwitz, 1993;
Wang et al., 1993).
There are no reports to our knowledge on allele loss of the
Wilms' tumour gene WTI (lIp13) or the neurofibromatosis
type 1 gene NFI (17q 1), which are both tumour-suppressor
genes, in colorectal cancer. The NFI gene product is involved
in the ras signal transduction pathway and could therefore be
of importance in other cancers. The NFl product has
GTPase-activating protein (GAP) activity, which can down-
regulate ras. There has been one study of NFI in colorectal
cancer, which looked at mutations of the gene (Li et al.,
1992), and in the one case of mutated NFI found the mutant
protein had 200-400 times reduced GAP activity.
The drawbacks to the use of RFLPs in allele loss studies
include the amount and quality of DNA required and the
length of time to produce results when using radioisotopic
detection methods. Microsatellites are DNA sequence
polymorphisms which exhibit length polymorphisms and are
usually highly informative (Weber & May, 1989). Allele loss
can be detected using microsatellites in a radioactive PCR
assay (Jones & Nakamura, 1992; Gruis et al., 1993). We
recently developed a fluorescence-based microsatellite PCR
assay to detect and quantitate allele loss (Cawkwell et al.,
1993) which made several improvements to the radioisotopic
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assay. Using this assay with intragemc markers where possi-
ble, we aimed to assess the possibility of multiplexing a
number of markers to simplify such studies. We went on to
determine the frequency of allele loss specific to DCC, p53,
RBJ, WTI, NFI, NM23 and the APC/MCC region. To our
knowledge no microsatellite polymorphisms have as yet been
identified at the APC locus and thus for this region, which
also contains the MCC gene, we had to use markers which
are closely linked to APC. Wherever possible two microsatel-
lite markers for each locus were assayed. The use of a
four-colour detection system enabled us to devise multiplex
PCR assays in order to assess allele loss at several loci
simultaneously.
We aimed to develop a panel of rapid gene-specific assays
in order to assess the importance of the above genes in
colorectal cancer.
Materials and methods
Samples
Freshly frozen samples of colorectal adenocarcinomas were
obtained from 20 patients at Leeds General Infirmary
between 1983 and 1987. Fresh normal colorectal tissue taken
from as far away from the tumour as possible was also
obtained from each patient. The range of age at operation
was 36-82 years, and 11 of the patients were male. There
were 15 left-side and 5 right-side tumours. There were one
Dukes stage A, nine Dukes stage B and ten Dukes stage C
tumours. Sections were stained with haematoxylin and eosin
and assessed by an experienced gastrointestinal pathologist.
All tumour sections used contained at least 50% malignant
cells.
DNA extraction
DNA was extracted using a proteinase K digestion method
as described by Bell et al. (1991).
Primer sequences
The APC (1) primers amplify a CA repeat motif at the
D5S299 locus proximal to, and linked to, APC (van Leeuwen
et al., 1991). The sequences were 5'-GTAAGCAGGACAAG-
ATGACAG and 5'-GCTATTCTCTCAGGATCITTG (van
Leeuwen et al., 1991) and give products of 156-182bp.
The APC (2) primers amplify a CA repeat at the D5S82
locus, which is proximal to APC (Breukel et al., 1991). The
sequences were 5'-CCCAATTGTATAGATFTTAGAAGTC
and 5'-ATCAGAGTATCAGAATTTCT (Breukel et al.,
1991) and give products of 169-179bp. The p53 (1) primers
amplify a CA repeat at the p53 locus (Jones & Nakamura,
1992). The sequences were 5'-AGGGATACTATTCAGCCC-
GAGGTG and 5'-ACTGCCACTCCTTGCCCCATTC (Jones
& Nakamura, 1992) and give products of 103-135 bp.
The p53 (2) primers amplify an AAAAT 5 bp repeat in the
first intron of the p53 gene (Futreal et al., 1991). The reverse
primer sequence was 5'-AACAGCTCCTTT-lAATGGCAG
(Futreal et al., 1991), but the forward primer (5'-GAATC-
CGGGAGGAGGTTG) was designed from the p53 genomic
DNA sequence in order to develop a simple PCR assay. This
marker gives products of 140-175 bp.
The DCC (1) primers amplify a TA repeat in an intron of
DCC (Fearon et al., 1990; Risinger & Boyd, 1992). The
sequences were 5'-TCCCTCTAGAAATTGTGTG and 5'-
TGACTITATCTCATTGGAG (Risinger & Boyd, 1992) and
gives products of 106-160 bp. The DCC (2) primers are an
alternative set of amplimers which amplify the same TA
repeat as the DCC (1) primers. The sequences were 5'-
GATGACATlTTTCCCTCTAG and 5'-GTGGTTATTGCC-
TTGAAAAG (Huang et al., 1992) and give products of
150-210 bp.
The RBJ primers amplify a CTTT(T) 4-5 bp repeat in
intron 20 of the RBI gene (Yandell & Dryja, 1989). The
sequences were 5'-CTCCTCCCTACT-TACTTGT (Huang et
al., 1992) and 5'-AATlTAACAAGGTGTGGTGGTACACG
(Onadim et al., 1992) and give products of 266-306bp.
The WTI primers amplify a CA repeat in the 3' untrans-
lated region of WTJ (Haber et al., 1990). The sequences were
5'-AATGAGACTTACTGGGTGAGG and 5'-TTACACAG-
TAATTITCAAGCAACGG (Haber et al.. 1990) and give
products around 144 bp.
The NM23-HI primers amplify a CA repeat at the NM23-
HI locus (Hall et al., 1992). The sequences were 5'-TT-
GACCGGGGTAGAGAACTC and 5'-TCTCAGTACTITC-
CCGTGACC (Hall et al., 1992) and give products of
94-104 bp.
The NFI primers amplify a CA repeat in intron 38 of the
NFl gene (Lizaro et al., 1993). The sequences were 5'-
CAGAGCAAGACCCTGTCT AND 5'-CTCCTAACATTT-
ATTAACCTTA (Lizaro et al., 1993) and give products of
171-187 bp.
Primer synthesis, labelling andpurification
For each primer pair one primer only was fluorescently
labelled. This was so that only one DNA strand was detected
on the gel, which made interpretation easier. All primers
were synthesised on a model 391 DNA synthesiser (Applied
Biosystems, Foster City, CA, USA). Using red (rox) as the
size standard colour we had three colours available (green,
blue and yellow), with the choice of five fluorochromes
(Applied Biosystems). Yellow primers were produced by
using the tamra fluorochrome (dye-NHS ester), the blue
primers were produced using either 5'fam (dye-NHS ester) or
6'fam amidite, and the green primers were produced using
using either joe (dye-NHS ester) or hex amidite.
Non-fluorescent primers Non-fluorescent primers required
no purification before use in PCR and were stored in concen-
trated ammonia at -20'C. The ammonia was removed prior
to each PCR by evaporation in a vacuum desiccator.
Fluorescent primers Two different methods were used to
fluorescently label the primers using either dye-NHS esters or
dye-amidites.
1. Dye-NHS ester method. This method was as described in
Cawkwell et al. (1993).
2. Dye-amidite method. Primers were synthesised by stan-
dard phosphoramidite chemistry on a model 391 DNA
synthesiser (Applied Biosystems), with the fluorescent
dye incorporated into the 5' site via a fluorescent dye-
amidite (Applied Biosystems). After elution and depro-
tection the fluorescent oligonucleotide was dried in a
centrifugal evaporator, resuspended in 201Al of distilled
water, and applied to a thin-layer chromatography plate
(Surepure oligonucleotide purification system, United
States Biochemicals, Cleveland, OH, USA). The purified
fluorescent primer was eluted from the plate in distilled
water.
Polymerase chain reaction
The target DNA sequences were amplified by the PCR in
25pl of 1 x Taq polymerase reaction buffer (Promega Cor-
poration, Madison, WI, USA) containing 12.5 pmol of each
primer (one fluorescent), 0.75 units of Supertaq Taq poly-
merase (HT Biotechnology, Cambridge, UK), 1.5 mM magne-
sium chloride, 50JlM each ofdATP, dCTP, dGTP, dTTP and
25-50 ng of sample DNA. This was overlaid with mineral oil.
The DNA was amplified in an MJ Research Thermal Con-
troller (Genetic Research Instrumentation, Dunmow, Essex,
UK) by one cycle at 95°C for 5 min, 55°C for 1 min followed
by an average of 22 cycles consisting of 95°C for 30 s and
55°C for 1 min. The annealing temperature was reduced to
50°C for the DCC (1) primers and to 52°C for the NFI
primers. The cycle number was optimised for each DNA
sample to ensure that the PCR products were detectable but
were not overamplified, as this caused the quantitation ofALLELE LOSS IN COLORECTAL TUMOURS 815
peak area to be inaccurate and therefore unusable. A
thermoprobe was included in a sample tube containing
mineral oil alone to ensure that the samples reached the
programmed cycle temperature before the timing of the cycle
begani.
Multiplex PCR
Multiplex PCR assays were designed on the basis that co-
amplified products would be distinguished either by colour or
by size range. The method for multiplex PCR was the same
as above except that more than one set of primers were
added to the same tube.
Polyacrylaunide gel electrophoresis
PCR products were analysed on 6% polyacrylamide (Gelmix-
6, Gibco BRL, Uxbridge, Middlesex, UK) denaturing gels in
1 x TBE buffer in a model 373A (four filter wheel) auto-
mated fluorescent DNA sequencer (Applied Biosystems),
which is a four-colour detection system. One microlitre of
each PCR reaction was combined with 4g of formamide
and 0.5pi of a fluorescent size marker (GS2500P, Applied
Biosystems). This mix was denatured for 3 min at 90-C, after
which 5il was loaded into each well on the prewarmed gel.
The tumour DNA samples were loaded 5 min after the nor-
mal samples so that any lane-to-lane spillage would not affect
the subsequent quantitation. The internal size standard for
each sample enables staggered loading to be carried out. The
gel was run at 30 W and 40C for 4 h except when using the
RBI primers, which required 6 h. While the samples were
undergoing electrophoresis the fluorescence detected in the
laser cnning region was collected and stored using the
Genescan Collection software (Applied Biosystems).
Data analysis
The fluorescent gel data collected during the run were autom-
atically analysed by the Genescan Analysis program (Applied
Biosystems), using the appropnate dye matrix, at the end of
the run. Each fluorescent peak was quantitated in terms of
size (in base pairs), peak height and peak area.
Calculation ofallele ratios
Allele ratios were caculated as described in Cawkwell et al.
(1993). The siz of the two alleles for heterozygous cases
were assigned according to the two peaks of greatest heght
in the normal sample. The values for peak area of the two
alleles in the paired normal and tumour samples were used to
assign a figure for allele loss. The ratio of alleles was cal-
culated for each paired normal and tumour sample and then
tumour ratio was divided by the normal ratio, i.e. T1:T2/
N1:N2, where T, and N, are the area values of the shorter
length allele peak and T2 and N2 are the area vahls of the
longer length allele peaks for the tumour (T) and normal (N)
sample. In cases where the allele ratio was above 1.00, a
conversion was made using 1/4T,:T2/N1:NJ to give a result
range of 0.00-1.00. A ratio of less than or equal to 0.50 was
taken to be indicative ofalele loss (Cawkwell et al., 1993) to
allow for up to 50% contaminating normal cells in the
tumour sample. All assays were performed at least twice, to
ensure that consistent results were obtained, and then the
mean vale was taken. In the case ofoveramplified products,
which would give unreliable area values, an aliquot of the
PCR product was diluted in distilW water and rerun on a
subsequent gel.
Microsatellite instability
Samples which consistently exhibited novel allele peaks in the
tumour sample, as compared with the corresponding normal
sample, for a particular marker were classed as being affected
by microsatellite instability at that marker. Such markers
were classed as uninformative for the allele loss study.
Rests
Our assay is based on the alteration of allele ratio in the
tumour when compared with the ratio in the corresponding
normal sample, and as such will not distinguish between
allele loss and amplification. Therefore it would be more
accurate to describe the results of our assay in terms ofallele
imblances, rather than loss, since the RB) gene has been
noted to undergo both loss and amplification.
The product size ranges we observed, as sized by the
GS2500P standard (Applied Biosystems), were: APC (1),
158-192 bp; APC (2), 173-183 bp; p53 (1), 109-127 bp; p53
(2), 145-165 bp; DCC (1), 115-155 bp; DCC (2), 169-
214bp; RBI, 274-305bp; WTI, 138-150 bp; NFI, 173-191
bp; NM23, 94-108 bp.
In the case of DCC we had two different sets of primers
available to amplify the same TA repeat, but we found that
the DCC (2) primers, which give longer products, were much
easier to interpret than the DCC (1) primers, and so the DCC
(2) primers will be used in the future.
Representative examples of the electropherograms are
shown in Figures 1 and 2.
Both the dye-NHS ester- and the dye-amidite-labelled
primers worked well, but the amidite dyes required less
manipulation. The tamra dye was consistently found to be
less intense than any of the blue or green dyes.
We observed prferential amplification of shorter products
over larger products (Figure 1). This affected the success of
some multiplex designs since markers which gave products of
shorter length would be overamplified in relation to markers
which gave longer length products. This was especially evi-
dent with the NM23 primers, but overamplification could
usually be corrected by diluting an aliquot of the PCR
product.
Some microsatellites produce 'stutter bands', which are
PCR artefacts (Litt, 1991; Hauge & Litt, 1993) and can make
interpretation of results difficult from autoradiographs. The
fluorescence-based system overcame this problem in most
cases. The p53 (1) and DCC (1) markers, which are 2bp
repeats, were the most problematic in terms of interpretation
of results owing to excess stutter bands. The longer 4-5 bp
repeat markers were not prone to this artefact and thus the
alleles were much easier to distinguish.
The results are shown in Table I.
The use of microsatellites for allele loss studies facilitates
the identification of loci where microsatellite instability (Aal-
tonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993)
has occurred, and with the use of our fluorescence detection
method these are easily recognised (L. Cawklwell et al.,
manuscript in preparation). The finding of microsatellite in-
stability meant that such loci were designated uninformative
and thus the total number of informative cases was reduced.
The allele imbalance frequency was calculated as [Al/
(Al + N)] x 100%, i.e. excluding all loci which were either
homozygous or affected by microsatellite instability. Our
microsatellite instability results will be further described in a
separate paper (L. Cawkweli et al., manuscript in prepara-
tion).
Where two markers were used for a region we found no
discordance between the two results where both markers
were informative.
The frequencies of allele imbalance found were as follows:
APC/MCC region, 50% (8/16); p53, 66% (10/15); DCC,
29% (5/17); RB), 50% (7/14); WTI, 0% (0/10); NFI, 14%
(2/14); NM23, 0% (0/14).
Diwoss
We have used fluorescent multiplex PCRs in order to in-
crease throughput for quantitating allele imbalance at seven
suppressor loci in colorectal tumours. Our frequencies for
allele imbalance of the p53 and RBI loci are similar to the
finngs of others using RFLP probes and Southern blot
analvsis.816 L. CAWKWELL et al.
*- Lane 5: sample 13N: DCC(2)
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*0 Lane 6: sample 13C: DCC(2)
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Min. Size Peakheight Peak area Scan no.
2B, 5 212 169.11 1301 11555 2128
3B,5 236 189.37 265 2331 2368
48, 5 239 191.35 552 4907 2392
1B, 6 222 167.07 215 1568 2220
2B, 6 224 169.18 1345 11290 224
3B, 6 248 189.36 267 2171 2482
48, 6 250 191.37 609 5563 2506
Fiwe I Electropherogram showing products of the DCC (2) prime exhibiting the preferential amplification of shorter alleles
over longer alleles. The upper trace shows the normal sample and the lower trace the corresponding tumour sample. The x-axis
shows size in base pairs and the y-axes show peak height values. The table beneath shows the peak size (in base pairs), height and
area. The shorter allele is 169 bp and the longer allele is 191 bp.
Our frequency of loss in the APC/MCC region is also
similar to that reported by others, but an intragenic micro-
satellite in APC would still be preferred to ensure that no
deletions specific to APC are missed. The markers used here
for Sq are linked to APC, but this means that we may miss
small deletions. There is a CA repeat 30-70 kb downstream
of APC (Spirio et al., 1991) which we are using in further
studies, but no intragenic microsatellite polymorphisms
within APC have been reported.
The frequency of allele imbalance of DCC that we found,
however, is lower than that reported by RFLP probes but is
similar to the frequency found by Huang et al. (1993) using
the intragenic DCC (1) primers that we have also used. The
reason for our low frequency is not clear. We would have
expected all of our frequencies to be lower than expected if
there was a common problem with our technique. Thus we
have ruled out the possibilities that normal cell contamina-
tion of the tumour sample could have affected our results
and that the stringency of our allele loss calculation could
have produced our low frequency of DCC loss. Huang et al.
(1993) also found a low frequency when using the same TA
repeat markers, which could have indicated that there was a
problem with this marker. We have noted that there is a very
wide allele size range with this marker, and preferential
amplification of the shorter allele was often seen. This could
have affected the allele loss calculation if there was any
inconsistency in the peak area quantitation. However, all of
our results were repeated at least once and such inconsisten-
cies did not appear to occur. Thus there could be a true
difference in the frequency of DCC loss between our series
and other published series.
WTI does not appear to be of importance in colorectal
carcinogenesis, but the NFI gene may be involved in a
minority of cases. A further study of chromosome 17,
especially between 17p13 (p53) and 17qll (NFI), may be of
interest in the cases with allele imbalance at NFl to see
whether the deletion involving p53 encompassed the NFl
locus or whether the NFI region had been targeted
separately. The finding of no allele imbalance at NM23
(17q22) in these cases indicates that loss or gain of a whole
chromosome 17 had not occurred.
Our finding of no allele imbalance of NM23 supports the
finding of Whitelaw & Northover (1994), and thus the
involvement of NM23 in colorectal cancer remains
unresolved.
Table I Results for allele imbalance in colorectal tumours
Sample APCAPC p53 p53 DCC DCC
mumber (1) (2) (1) (2) (1) (2) RBI WTI NFl NM23
mMI MI MI H N N MI MI MI H
2 N N H N N N H N N N
3 N H H H Al AI Al N N N
4 Al H Al Al U Al Al N N N
5 N N N MI N N Al N N N
6 Al H Al H Al Al Al H N N
7 Al H Al H MI MI Al N N N
8 AI AI Al H H H N H N N
9 AI AI Al Al N N N N Al N
10 N MI MI N MI MI MI N Ml N
11 MI H MI H N N MI MI MI MI
12 MI MI MI H N N MI MI MI MI
13 N N H Al N N N N N H
14 N N H Al N N N H N N
15 N N U N N N N H N N
16 MI MI Ml H N N MI H MI H
17 H Al U AI N N N H N N
18 N N Al Al Al AI Al H Al N
19 AI AI U Al U Al Al N H H
20 H Al N N N N N N N N
H, homozygous; N, no allele imbalance; Al, allele imbalance; MI,
microsatellite instability; U, uninterpretable due to excess stutter
bands.
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Figwe 2 Multiplex PCR products for sample 8 for APC (1) in green, p53 (1) in blue and WTI in black. a, Normal sample; b,
Tumour sample. The WT) marker is uninformative but both the APC (1) and p53 (1) markers indicate allle imbalance [mean
alleie ratios calclated were 0.34 for APC (1) and 0.43 for p53 (1); for explanation of calculation see text]. Total loss of a peak is
not usually scen because of the normal cells wbich usually contaminte the tumour sample. The p53 (1) primers which amplify a
CA repeat rgion show excess stutter bands, which do not interfere with the caklulation.
The use of our fluorescent microsatellite assay has enabled
us to easily detect microsatellite instability. This caused prob-
lems with the allele imbalance study, since such loci had to
be classed as uninformative. However, the assay does enable
us to assess these two types of alteration simultaneously.
Multiplex design in future will take into account the
preferential amplification of short products over long pro-
ducts. To counteract this, the shortest products could be
labelled with the tamra dye since this is the weakest fluoresc-
ing dye. Alternatively, to counteract this effect, the separate
amplification of short products and long products would
enable the optimisation of both. The products could then be
mixed and co-loaded into a single lane on the gel.
The use of fluorescent multiplex PCR for allele imbalance
assays enabled us to assess several suppressor gene loci simul-
taneously. The most frequently occurring lesions in colorectal
cancer will now be studied in an extended series with accom-
panying clinical and follow-up data to see whether any alter-
ation, or specific combination of alterations, correlates with
clinical features or prognosis. We will then attempt to devise
a rapid and robust fluorescent multiplex PCR assay for allele
imbalance, preferably in a single tube, to assess all of these
important lesions simultaneously. Such a diagnostic test
could be important in screening, prognosis and therapy in
colorectal cancer, and in a modifed form in other
tumours.
In conclusion, in this preliminary study we have used rapid
and quantitative fluorescent multiplex PCR assays to detect
allele imbalance at several tumour-suppressor loci simultan-
eously, using microsatellite markers of 2-5 bp repeat motifs,
in order to identify the specific genes which undergo altera-
tion most frequently in sporadic colorectal tumours. These
assays also identified microsatellite instability.
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